Novo Nordisk's new weight loss pill, Wegovy, is off to a strong start in the U. S. Analysts say it was prescribed over 18, 000 times in its first full week. This is a big deal because it shows people are interested in a pill they can take instead of a shot.

The race to make the best weight loss pill is heating up. Novo Nordisk is hoping this new pill will help them stay ahead of their big rival, Eli Lilly. The first few days after the launch were especially good, with over 3, 000 prescriptions in just four days.

Why is this a big deal? Well, most weight loss treatments are still injections. But pills are easier for many people to take. This could be a game-changer.

Novo Nordisk has been having a tough time lately. Their sales have been slowing down, and their stock price has taken a hit. But this new pill might be just what they need to bounce back. Their stock has been going up steadily since the start of the year.

Eli Lilly is also working on a weight loss pill. The U. S. Food and Drug Administration is expected to make a decision on it by April. Analysts think this new pill from Novo could be a good sign for Eli Lilly's pill too.

People are also searching for Wegovy and NovoCare more on Google. This shows that there's a lot of interest in this new treatment. But injectable treatments are still the most popular, and that's not likely to change anytime soon.


# Novo Nordisk's Wegovy: A Strong Start in the Weight Loss Pill Race

**Novo Nordisk's new weight loss pill, Wegovy, is off to a strong start in the U.S.**

- **Over 18,000 prescriptions** in its first full week.
- **Big deal**: People prefer pills over shots.

## The Race Heats Up

- Novo Nordisk vs. Eli Lilly in the weight loss pill race.
- **First four days**: Over 3,000 prescriptions.

### Why It Matters

- Most weight loss treatments are still injections.
- **Pills are easier** for many people to take.
- **Game-changer** potential.

## Novo Nordisk's Struggles and Hope

- **Recent challenges**: Slowing sales, stock price hit.
- **Wegovy's launch**: Stock has been rising since the start of the year.

## Eli Lilly's Contender

- Also working on a weight loss pill.
- **FDA decision expected by April**.
- **Analysts**: Novo's success could bode well for Eli Lilly.

## Public Interest

- **Google searches**: Increased for Wegovy and NovoCare.
- **Popularity**: Injectable treatments still lead, but pills gaining interest.



Weight Loss Pills: Novo's Wegovy Makes a Splash in First Week

The Race Heats Up

Why It Matters

Novo Nordisk's Struggles and Hope

Eli Lilly's Contender

Public Interest

Actions